Efficacy and Safety of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain

Phase 2

Terminated

• Conditions: Constipation

• Registration Number: NCT00365820
• Lead Sponsor: Novartis

Brief Summary

This study will evaluate the efficacy and safety of tegaserod in opioid-induced constipation in patients with non-cancer pain.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2006-07
• Study First Submitted: 2006-08-17
• Study First Submitted QC: 2006-08-17
• Study First Posted: 2006-08-18
• Primary Completion: 2007-04
• Study Completion: 2007-04
• Status Verified: 2012-04
• Last Update Submitted: 2012-04-19
• Last Update Posted: 2012-04-20

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 670

Inclusion Criteria

1. Male and female outpatients 18 years of age or older.

2. Patients with chronic non-cancer pain that necessitates the use of non-injectable opioid analgesics. The equivalent dose of 300 mg morphine per day is the maximum opioid analgesic dose allowed. In general, patients should be using opioids on a daily basis.

3. Chronic pain which has been present for a minimum of 3 months which needs the chronic use of opioids for pain relief.

4. Constipation, according to the investigator's clinical judgment, that is resulting from opioid use for non-cancer chronic pain. Opioid-induced constipation (OIC) is defined as follows:

   • less than 3 spontaneous bowel movements per week and at least one of the following on at least 25% of occasions:

     1. hard or very hard stools
     2. sensation of incomplete evacuation
     3. straining while having a bowel movement

Read More

Exclusion Criteria

1. Patients who are receiving opioids for abdominal pain or connective tissue disorders.
2. Planned discontinuation or an increase or decrease by more than 30% of the current opioid dose
3. Patients who underwent major surgery within 3 months prior to screening.
4. Patients with a history of prior chronic constipation (CC) that was present for more than three months and that was not related to opioid use.
5. Patients with a current diagnosis of irritable bowel syndrome (IBS) constipation predominant or alternators.

Other protocol-defined inclusion/exclusion criteria may apply.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Change from baseline in the number of bowel movements over weeks 1-4

Secondary Outcome Measures

Name	Time	Method
Change from baseline in the number of bowel movements over weeks 1-12
Change from baseline in abdominal distension/bloating over weeks 1-12
Change from baseline in abdominal discomfort/pain over weeks 1-12

Trial Locations

Locations (2)

Novartis Pharmaceutical Corporation; 🇺🇸 East Hanover, New Jersey, United States

Investigative Site; 🇺🇸 Seattle, Washington, United States